A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.
Ninomiya T, Ishikawa N, Kozuki T, Kuyama S, Inoue K, Yokoyama T, Kanaji N, Yasugi M, Shibayama T, Aoe K, Ochi N, Fujitaka K, Kodani M, Ueda Y, Watanabe K, Bessho A, Sugimoto K, Oze I, Hotta K, Kiura K.
Ninomiya T, et al. Among authors: aoe k.
Lung Cancer. 2023 Oct;184:107349. doi: 10.1016/j.lungcan.2023.107349. Epub 2023 Aug 19.
Lung Cancer. 2023.
PMID: 37651927
Clinical Trial.